Pfizer Yönetim
Yönetim kriter kontrolleri 3/4
Pfizer CEO'su Albert Bourla, Jan2019 tarihinde atandı, in görev süresi 7.33 yıldır. in toplam yıllık tazminatı $ 27.59M olup, şirket hissesi ve opsiyonları dahil olmak üzere 6.5% maaş ve 93.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.007% ine doğrudan sahiptir ve bu hisseler $ 10.23M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6 yıl ve 7.5 yıldır.
Anahtar bilgiler
Albert Bourla
İcra Kurulu Başkanı
US$27.6m
Toplam tazminat
| CEO maaş yüzdesi | 6.53% |
| CEO görev süresi | 7.3yrs |
| CEO sahipliği | 0.007% |
| Yönetim ortalama görev süresi | 6yrs |
| Yönetim Kurulu ortalama görev süresi | 7.5yrs |
Son yönetim güncellemeleri
Recent updates
Seeking Alpha • May 18
Why Pfizer Stock Still Looks Deeply Undervalued In 2026
Summary Marty Makary resigned from his position as FDA Commissioner on May 12, in my view, in part because of his inconsistent policy approach. The FDA leadership shake-up continues to this day, but as I'll explain below, this period of uncertainty isn't creating pressure on Big Pharma players, including Pfizer. By the way, Pfizer is still my favorite in the oncology drugs market, trading at a non-GAAP P/E ratio of 8.6x and a high 6.8% dividend yield. In Q1, Padcev sales were $591 million, up 16.3% QoQ and 38.7% YoY, mainly due to increased demand for its use in combination with Merck's Keytruda for treatment of MIBC. Next, I'llpresent five more key factors explaining why I continue to cover Pfizer with a'Strong Buy' rating. Read the full article on Seeking Alpha
Anlatı Güncellemesi • May 03
PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post Settlement Outlook
Pfizer's updated analyst price target has shifted slightly lower to $24.00 from $25.00 as analysts factor in a steeper projected revenue decline, a modestly higher profit margin outlook, and mixed views on the post-settlement pipeline and patent overhang. Analyst Commentary Recent research on Pfizer highlights a split view.
Anlatı Güncellemesi • Apr 19
PFE: GLP-1 And Oncology Advancements Will Support Post LOE Repricing
Pfizer's analyst fair value estimate has been adjusted modestly higher to $35.96 from $35.33, as analysts factor in recent price target raises and mixed views on the post-2028 pipeline, loss of exclusivity risks, and evolving expectations for the GLP-1 and oncology portfolios. Analyst Commentary Recent Street research on Pfizer reflects a split view, with some firms expressing caution around patent expiries and near term visibility, while other bullish analysts focus on the potential in GLP-1 and oncology programs, along with broader sector appeal in healthcare.Anlatı Güncellemesi • Apr 05
PFE: Obesity And Oncology Pipeline Progress Will Drive Post LOE Rerating
Analysts have nudged Pfizer's implied fair value modestly higher to about $35.33 per share, citing recent price target increases of around $1 to $3 and research that highlights contributions from its GLP-1, oncology, and hematology pipelines, while also noting the long-term patent cliff and revenue uncertainty. Analyst Commentary Recent research on Pfizer shows a split view, with some firms highlighting long term headwinds from loss of exclusivity while others point to pipeline depth and business development as potential offsets.Anlatı Güncellemesi • Mar 22
PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post 2028 Outlook
Pfizer's updated analyst narrative keeps fair value steady at $25.00, with recent Street research showing price targets clustering from $25.00 to $35.00 as analysts weigh concerns about a post-2028 patent cliff against interest in the GLP-1, oncology, and collaboration pipelines, as well as healthcare's perceived appeal in a riskier macro backdrop. Analyst Commentary Recent Street research around Pfizer reflects a split view, with some firms pointing to potential in GLP-1, oncology, hematology, and collaborations, while others emphasize the scale and timing of the expected revenue cliff and limited visibility on offsets.Anlatı Güncellemesi • Mar 08
PFE: Patent Cliff And GLP 1 Pipeline Will Shape Next Decade
Analysts lifted their fair value estimate for Pfizer from $23.00 to $25.00 per share, reflecting updated views that weigh a stronger GLP 1 and oncology pipeline against ongoing concerns about the patent cliff and near term revenue visibility. Analyst Commentary Recent Street research on Pfizer presents a mixed picture, with more cautious voices focusing on patent expirations, limited near term pipeline visibility, and questions around how quickly new therapies can support growth.Anlatı Güncellemesi • Feb 21
PFE: Obesity Pipeline Progress Will Drive Post LOE Re Rating
Pfizer's updated analyst price target edges lower to about $35 per share. This reflects analysts' focus on ongoing losses of exclusivity, a slightly softer revenue and margin outlook, and tempered expectations for future P/E as some firms initiate or assume coverage with more cautious views around the next few years.Anlatı Güncellemesi • Feb 07
PFE: Obesity Pipeline And LOE Headwinds Will Shape Future Re Rating
Narrative Update Analysts have trimmed their fair value estimate for Pfizer from $36.16 to $35.46, reflecting more cautious assumptions on revenue trends and profit margins, even as some on the Street highlight new assets and deals that they believe could support a higher future P/E multiple. Analyst Commentary Recent Street research on Pfizer highlights a mix of caution and optimism, with several firms reassessing how the pipeline and recent deals might offset upcoming patent expiries and support the valuation over time.Anlatı Güncellemesi • Jan 24
PFE: Loss Of Exclusivity And Obesity Deal Costs Will Pressure Shares
Analysts have reduced their fair value estimate for Pfizer from $24.00 to $23.00 per share, citing lower revenue and margin assumptions, a slightly higher discount rate, and cautious views on patent expiries, while still noting ongoing interest in its pipeline and licensing deals. Analyst Commentary Recent Street research around Pfizer has been mixed, with some firms highlighting long term opportunities in areas like obesity and licensing, while others are stressing near term execution and patent expiry risks.Anlatı Güncellemesi • Jan 10
PFE: Obesity Deal And LOE Overhang Will Shape Re Rating Potential
Analysts have trimmed their price expectations for Pfizer, citing ongoing revenue uncertainty around an expected US$15b to US$20b loss of exclusivity over the next few years, even as some see support from the obesity deal and a broader positive stance on large cap biopharma. Analyst Commentary Recent research highlights a split view on Pfizer, with some caution around the expected US$15b to US$20b loss of exclusivity over the next few years and others pointing to potential upside linked to obesity treatments and a broader positive stance on large cap biopharma.Analiz Makalesi • Jan 08
Pfizer (NYSE:PFE) Has Announced A Dividend Of $0.43
Pfizer Inc. ( NYSE:PFE ) will pay a dividend of $0.43 on the 6th of March. This makes the dividend yield 6.8%, which...Anlatı Güncellemesi • Dec 25
PFE: Obesity Bid And Margin Outlook May Drive Re-Rating Ahead
Analysts have nudged their price target on Pfizer higher by $2 to $30, citing improving margin expectations and a more constructive sector backdrop, despite tempered revenue growth assumptions. Analyst Commentary Bullish analysts highlight that the latest price target increase reinforces a gradually improving sentiment toward Pfizer, with investors starting to look past the near term revenue slowdown and focus more on medium term cash flow durability and pipeline execution.Analiz Makalesi • Dec 18
Pfizer (NYSE:PFE) Has Affirmed Its Dividend Of $0.43
The board of Pfizer Inc. ( NYSE:PFE ) has announced that it will pay a dividend of $0.43 per share on the 6th of March...
Anlatı Güncellemesi • Dec 11
PFE: Obesity Pipeline Expansion Will Drive Upside Amid Sector Rerating
Analysts nudged their price target on Pfizer higher to $30 from $28, citing a sector wide rerating on benign U.S. drug pricing developments and the strategic upside from an expanded obesity pipeline and broader large cap biopharma innovation. Analyst Commentary Bullish analysts highlight that Pfizer is benefiting from a constructive shift in U.S. drug pricing expectations and a broader rerating of large cap biopharma, which supports the recent price target increase and stabilizes valuation multiples.Anlatı Güncellemesi • Nov 13
PFE: Obesity Deal Will Drive Upside After Sector Underperformance And Portfolio Shifts
Pfizer’s analyst price target was raised from $28 to $30 per share, reflecting a modest increase in fair value. Analysts cite sector-wide re-rating and updated fundamentals, including acquisition activity and anticipated drug pipeline developments, as key drivers for the revision.Analiz Makalesi • Aug 12
Solid Earnings Reflect Pfizer's (NYSE:PFE) Strength As A Business
NYSE:PFE 1 Year Share Price vs Fair Value Explore Pfizer's Fair Values from the Community and select yours Pfizer...Seeking Alpha • Apr 30
Pfizer's Q1 Update May Mark A Bottom In The Stock
Summary Pfizer is facing some revenue pressures due to some higher Medicare discounts, and this has led to a small miss on revenue delivery in Q1 FY25. Pfizer is making meaningful improvements on profitability and is on track to realize a ~12.3% margin lift from 2024 until the end of 2027 from various cost saving initiatives. Stopping R&D of an obesity drug that had $10 billion annual revenue potential is a major setback and if PFE tries M&A instead, there is a risk of overpaying again. PFE stock is trading at trough valuations and at a larger-than-usual discount vs peers. So I think there is some decent margin of safety. Technical analysis vs SPX500 suggests PFE may be forming a bottom, but strong buyer signals are still absent. Read the full article on Seeking AlphaCEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 29 2026 | n/a | n/a | US$7b |
| Dec 31 2025 | US$28m | US$2m | US$8b |
| Sep 28 2025 | n/a | n/a | US$10b |
| Jun 29 2025 | n/a | n/a | US$11b |
| Mar 30 2025 | n/a | n/a | US$8b |
| Dec 31 2024 | US$25m | US$2m | US$8b |
| Sep 29 2024 | n/a | n/a | US$4b |
| Jun 30 2024 | n/a | n/a | -US$3b |
| Mar 31 2024 | n/a | n/a | -US$288m |
| Dec 31 2023 | US$22m | US$2m | US$2b |
| Oct 01 2023 | n/a | n/a | US$10b |
| Jul 02 2023 | n/a | n/a | US$21b |
| Apr 02 2023 | n/a | n/a | US$29b |
| Dec 31 2022 | US$33m | US$2m | US$31b |
| Oct 02 2022 | n/a | n/a | US$30b |
| Jul 03 2022 | n/a | n/a | US$29b |
| Apr 03 2022 | n/a | n/a | US$25b |
| Dec 31 2021 | US$24m | US$2m | US$22b |
| Oct 03 2021 | n/a | n/a | US$19b |
| Jul 04 2021 | n/a | n/a | US$12b |
| Apr 04 2021 | n/a | n/a | US$9b |
| Dec 31 2020 | US$21m | US$2m | US$7b |
| Sep 27 2020 | n/a | n/a | US$212m |
| Jun 28 2020 | n/a | n/a | US$7b |
| Mar 29 2020 | n/a | n/a | US$9b |
| Dec 31 2019 | US$18m | US$2m | US$11b |
Tazminat ve Piyasa: Albert 'nin toplam tazminatı ($USD 27.59M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 14.84M ).
Tazminat ve Kazançlar: Albert 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Albert Bourla (63 yo)
7.3yrs
Görev süresi
US$27,585,301
Tazminat
Dr. Albert Bourla, DVM, Ph.D. serves as Chairman & CEO at Pfizer Venture Investments LLC. He serves as CEO from January 2019. He serves as the Chief Executive Officer of Pfizer Inc. since January 1, 2019 a...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chairman of the Board & CEO | 7.3yrs | US$27.59m | 0.0069% $ 10.2m | |
| Executive VP & CFO | 4yrs | US$9.67m | 0.00067% $ 990.9k | |
| Chief Scientific Officer and President of Research & Development | 1.3yrs | US$10.01m | 0.0028% $ 4.2m | |
| Executive VP & Chief Legal Officer | 12.4yrs | US$9.11m | 0.0029% $ 4.3m | |
| Executive VP & Chief U.S. Commercial Officer | 4.8yrs | US$9.43m | 0.00052% $ 769.1k | |
| Senior VP | 6.2yrs | Veri yok | 0.00058% $ 857.8k | |
| Executive VP & Chief Information Officer | less than a year | Veri yok | 0.00083% $ 1.2m | |
| Chief Investor Relations Officer | no data | Veri yok | Veri yok | |
| Chief People Experience Officer & Executive VP | 5.9yrs | Veri yok | 0.00074% $ 1.1m | |
| Senior VP and Chief Scientific Officer of Inflammation & Immunology | 10yrs | Veri yok | Veri yok | |
| Chief Scientific Officer of Oncology | 6.8yrs | Veri yok | Veri yok | |
| Senior VP & Chief Scientific Officer of Rare Disease | no data | Veri yok | Veri yok |
6.0yrs
Ortalama Görev Süresi
59yo
Ortalama Yaş
Deneyimli Yönetim: PFE 'un yönetim ekibi deneyimli ve deneyimlidir ( 6 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chairman of the Board & CEO | 6.3yrs | US$27.59m | 0.0069% $ 10.2m | |
| Independent Director | 6.1yrs | US$380.52k | 0.000060% $ 88.7k | |
| Lead Independent Director | 12.7yrs | US$410.00k | Veri yok | |
| Independent Director | 9.3yrs | US$360.00k | 0.00057% $ 843.0k | |
| Independent Director | 18.7yrs | US$410.00k | 0.00018% $ 266.2k | |
| Independent Director | 11.9yrs | US$390.00k | 0.000060% $ 88.7k | |
| Independent Director | 1.6yrs | US$360.00k | Veri yok | |
| Independent Director | 8.2yrs | US$380.00k | Veri yok | |
| Independent Director | 6.3yrs | US$380.00k | Veri yok | |
| Independent Director | 1.9yrs | US$380.00k | 0.00018% $ 266.2k | |
| Independent Director | 6.9yrs | US$393.50k | 0.00018% $ 266.2k | |
| Independent Director | 10.9yrs | US$400.37k | Veri yok |
7.5yrs
Ortalama Görev Süresi
64yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: PFE 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.5 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/22 18:10 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2026/03/29 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Pfizer Inc. 44 Bu analistlerden 26, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Kerry Holford | Berenberg |